Corbus Reports Strong CRB-701 Data in HPV-Driven Cancers, Sets Registrational Trial

Event summary

  • CRB-701 showed 42.9% ORR in 2L oropharyngeal cancer and 34.4% in 2L cervical cancer at 3.6 mg/kg dose.
  • Median DOR was 6.3 months in OPSCC and 8.0 months in cervical cancer.
  • TEMPO-1 registrational trial in OPSCC to begin summer 2026 with FDA-aligned design.
  • CRB-701 demonstrated favorable safety profile with low discontinuation rates (2.8%).
  • ASCO presentations scheduled for May 29–30, 2026, with KOL event on June 1.

The big picture

Corbus' data validates its strategy of targeting Nectin-4 in HPV-driven cancers with high unmet need. The upcoming registrational trial positions CRB-701 as a potential new standard in 2L OPSCC, where current options are limited. Success could expand Corbus' oncology footprint beyond urothelial cancer.

What we're watching

Trial Execution
Whether TEMPO-1 can deliver confirmatory data to support accelerated approval.
Commercial Path
The pace at which Corbus can establish CRB-701 in HPV-driven cancer indications.
Competitive Positioning
How CRB-701 differentiates against existing therapies in 2L OPSCC and cervical cancer.

Related topics

Oncology